Unibest

Pharmaceutical intermediates

Ribociclib Succinate Intermediates

2 pharmaceutical intermediates for Ribociclib Succinate. Indication: Breast cancer.

提交项目All intermediates

About Ribociclib Succinate

Originator
Novartis Pharmaceuticals Corp
Indication
Breast cancer
Approved Date
03/13/2017
DS/DP
06/17/2028

Available intermediates

2 intermediates currently listed for Ribociclib Succinate. Request specifications, documentation or a quotation for any item below.

Ribociclib Succinate intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2-Chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid1211443-58-1//
2-Chloro-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6- carboxamide1211443-61-6//

Other programs under R

Ramelteon RegorafenibRelugolixRemdesivir RemibrutinibRepotrectinibResmetiromRevumenib

Building toward Ribociclib Succinate?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →